Published in Cancer Weekly, June 21st, 2005
Trial 006, a randomized double-blind, placebo-controlled study, assessed the safety and efficacy of combining ZD6474 with the chemotherapy agent docetaxel (Taxotere) compared to docetaxel alone in patients with previously treated advanced non-small cell lung cancer (NSCLC).
Preliminary analysis of the trial 006 data showed that the primary endpoint of improved progression free survival (PFS) was met. Patients receiving ZD6474 100 mg plus docetaxel had a median PFS of 18.7 weeks, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.